{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"<= Day 12 post transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Day 13 to 21 post transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":">= Day 22 post transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Unknown"}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"10"}],"units":"transplantations"}],"description":"Platelet (PLT) engraftment was defined as a PLT count of ≥ 20\\*10\\^9/L for 7 days without transfusion. Days to engraftment corresponded to the first day that the criteria were met after transplantation.","groups":[{"description":"Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.","id":"OG000","title":"Participants With Multiple Myeloma (MM)"}],"paramType":"NUMBER","populationDescription":"Intent to treat population includes participants who received plerixafor and underwent transplantation. One participant had two transplants. One participant did not have PLT samples collected (included as 'unknown' in data table).","reportingStatus":"POSTED","timeFrame":"Approximately 2 months","title":"Number of Transplantations That Achieved Platelet (PLT) Engraftment Grouped by Days to Engraftment","type":"SECONDARY","typeUnitsAnalyzed":"transplantations","unitOfMeasure":"transplantations"}